Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
agenT-797 + pembrolizumab + nivolumab
- Development stage
- Unknown
- Lead developer
- MiNK Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
agenT-797 + pembrolizumab + nivolumab is an investigational combination therapy consisting of an allogeneic invariant natural killer T (iNKT) cell therapy (agenT-797) and approved anti-PD-1 immune checkpoint inhibitors (ICIs). Developed by MiNK Therapeutics, agenT-797 is an off-the-shelf, unmodified biologic that leverages the dual properties of innate and adaptive immunity to target solid tumors. Unlike traditional CAR-T therapies, agenT-797 does not require HLA matching or lymphodepletion. When administered alongside ICIs such as pembrolizumab (Keytruda) or nivolumab (Opdivo), the therapy is designed to overcome checkpoint inhibitor resistance by promoting immune cell infiltration and restoring anti-tumor activity in the tumor microenvironment. This combination is currently in Phase 1 clinical development for patients with relapsed or refractory solid tumors.
- Brand names
- KeytrudaOpdivo
- Other names
- Approved ICIs-MiNK Therapeutics-Solid tumorsagenT-797 + Approved ICIsagenT-797 + immune checkpoint inhibitorsagenT-797 + pembrolizumabagenT-797 + nivolumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)
Beyond the preview
Go deeper on agenT-797 + pembrolizumab + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on agenT-797 + pembrolizumab + nivolumab.